Gender and polypharmacy | |||
---|---|---|---|
Variable | Number of prescribed medicinesa,b | p value (p < 0.05) | |
Gender | 3–15 | > 15 | 0.013* |
Female | 44.8% | 22.8% | |
Male | 26.4% | 6.0% |
The number of diagnosed clinical problems and type of prescriber contact | |||
---|---|---|---|
Variable | Number of diagnosed clinical problemsa | p value (p < 0.05) | |
Prescriber contact | 0–4 | 5–8 | 0.013* |
Level 2 | 62.0% | 12.8% | |
Level 3 | 17.2% | 8.0% |
Polypharmacy and type of prescriber contact | ||||
---|---|---|---|---|
Variable | Number of prescribed medicinesa | p value (p < 0.05) | ||
Prescriber Contact | 3–8 | 9–14 | > 15 | 0.01* |
Level 2 | 17.6% | 40.0% | 17.2 | |
Level 3 | 2.8% | 10.8% | 11.6% |
Polypharmacy and potential drug–drug interactions | |||
---|---|---|---|
Variable | Number of prescribed medicinesa,b | p value (p < 0.05) | |
Number of PDDIsa | 3–14 | > 15 | < 0.05* |
0–20 | 70.0% | 20.4% | |
> 21 | 1.2% | 8.4% |
Type of prescriber contact and potential drug–drug interactions | |||
---|---|---|---|
Variable | Number of PDDIsa | p value (p < 0.05) | |
Prescriber Contact | 0–20 | > 21 | 0.014* |
Level 2 | 69.6% | 5.2% | |
Level 3 | 20.8% | 4.4% |